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Abstract
Immunohistochemistry (IHC) using formalin-ﬁxed, parafﬁn embedded (FFPE) tissue is limited by epitope masking,
posttranslational modiﬁcation and immunoreactivity loss that occurs in stored tissue by poorly characterized mechanisms.
Conformational epitopes recognized by many programmed-death-ligand-1 (PD-L1) IHC assays are particularly susceptible
to degradation and provide an ideal model for understanding signal loss in stored FFPE tissue. Here we assessed 1206 tissue
sections to evaluate environmental factors impacting immunoreactivity loss. PD-L1 IHC using four antibodies (22C3, 28-8,
E1L3N, and SP142), raised against intracellular and extracellular epitopes, was assessed in stored FFPE tissue alongside
quantitative mass spectrometry (MS). Global proteome analyses were used to assess proteome-wide oxidation across an
inventory of 3041 protein groups (24,737 distinct peptides). PD-L1 quantitation correlated well with IHC expression on
unaged sections (R2= 0.744; P < 0.001), with MS demonstrating no loss of PD-L1 protein, even in sections with signiﬁcant
signal loss by IHC impacting diagnostic category. Clones 22C3 and 28-8 were most susceptible to signal loss, with E1L3N
demonstrating the most robust signal (56%, 58%, and 33% reduction respectively; p < 0.05). Increased humidity and
temperature resulted in signiﬁcant acceleration of immunoreactivity loss, which was mitigated by storage with desiccant. MS
demonstrated only modest oxidation of 274 methionine-containing peptides and aligned with IHC results suggesting peptide
oxidation is not a major factor. These data imply immunoreactivity loss driven by humidity and temperature results in
structural distortion of epitopes rendering them unsuitable for antibody binding following epitope retrieval. Limitations of
IHC biomarker analysis from stored tissue sections may be mitigated by cost-effective use of desiccant when appropriate. In
some scenarios, complementary MS is a preferred approach for retrospective analyses of archival FFPE tissue collections.
Introduction
Formalin-ﬁxation followed by parafﬁn embedding is the
most widely used method for preparing and preserving
tissue specimens for clinical and research purposes world-
wide. Obtaining, handling, and storing formalin-ﬁxed,
parafﬁn embedded (FFPE) tissue sections presents unique
challenges to global pharmaceutical research and develop-
ment. Standard tissue collections, often inﬂuenced by
geography and local regulations, can be limiting to the extent
that only sectioned tissues adhered to glass slides are avail-
able for analysis. This impacts robust biomarker develop-
ment, since stored FFPE tissue is susceptible to degradation
that alters both protein and nucleic-acid assays [1–5]. Recent
approved biologics targeting the PD-1 (programmed cell
death protein 1) and programmed-death-ligand-1 (PD-L1)
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immune checkpoint axis utilize IHC for PD-L1 expression as
a complementary or companion diagnostic [6, 7], and PD-L1
immunoreactivity on tumor cells (TC) has been shown to
decrease during tissue storage [1, 8, 9]. The quantity of PD-
L1 expression is crucial for the prescribing of the associated
immuno-modulatory drugs; therefore, the instructions for use
of the FDA approved PD-L1 IHC assays recommend testing
tissues as soon as possible, but no later than 1–6 months for
most applications [10–13].
Previous studies have found antigen degradation to be
both antigen speciﬁc and condition dependent; therefore, a
detailed understanding of how speciﬁc handling and storage
conditions affect novel assays warrants greater appreciation
in earlier stages of development. FFPE tissue sections are
more prone to loss than tissue blocks [14, 15] and differing
environmental conditions can accelerate or mitigate loss of
antigenicity [3, 16–21]. However, there appears to be no
single factor responsible for antigen degradation: ﬁxation
methodology, storage time, ultraviolet A exposure, oxidation,
humidity, and temperature are all implicated [16, 22–24].
The difﬁculty of studying antigen degradation is further
compounded by the lack of deﬁned metrics for predicting and
measuring it with respect to speciﬁc assays.
An alternative approach to IHC for protein quantitation
in archival tissues is analysis by targeted mass spectro-
metry (MS) [25–27]. This method measures protein-
speciﬁc peptide sequences extracted from unstained FFPE
sections and enables precise quantitative comparisons of
protein abundances within individual samples and across
cohorts. The application of targeted MS to measure
PD-L1 and several other immune checkpoint and immu-
noregulatory proteins in archival FFPE sections from
melanomas has been described [27]. In this context, MS
and IHC measurements of PD-L1 were largely con-
cordant, except for samples in which PD-L1 was found to
be highly glycosylated by MS.
Here we describe a reproducible model of accelerated
antigen instability testing and use it to address questions
of how immunoreactivity is affected in stored tissue. We
speciﬁcally evaluate the role of protein oxidation in
antigen degradation, how different model IHC assays
respond to accelerated conditions, and how MS may be
used to evaluate and overcome the limitations of IHC in
detecting PD-L1 in stored FFPE tissue sections in the
research setting.
Materials and methods
Specimens studied
FFPE tissue blocks of non-small cell lung carcinoma
(NSCLC), gastric carcinoma, placenta, and tonsil tissue
were commercially acquired from Asterand Bioscience
(Detroit, MI, USA), US Biomax (Rockville, MD, USA),
Tristar Technology Group (Washington, DC, USA), and
Indiana University Health Methodist Hospital biobank
(Indianapolis, IN, USA) in either tissue microarray (TMA)
or whole section format. Tissue blocks were obtained
between 2012 and 2018. Some 1206 tissue sections were
evaluated from 35 gastric carcinomas [tubular adenocarci-
noma], 10 NSCLCs [2 primary squamous cell carcinoma
(SCC) and 8 primary adenocarcinoma (ADC)], 6 tonsil, and
6 placenta samples. Unless otherwise stated, microtomy was
performed immediately prior to experiment initiation.
Normal storage conditions refer to a monitored and con-
trolled laboratory environment with a relative humidity
range of 14.4–80.5% (average 46.8%) and a temperature
range of 20.1–31.0 °C (average 21.6 °C) where tissue sec-
tions were not exposed to direct light.
Immunohistochemistry
Serial sections were cut at 4-µm thickness and allowed to
dry at room temperature (RT) overnight. IHC staining for
PD-L1 was performed using four different anti-PD-L1
clones: PD-L1 IHC 22C3 pharmDx (Agilent; Santa Clara,
CA, USA) and PD-L1 IHC 28-8 pharmDx (Agilent) per
manufacturers guidelines; [10, 11] Cell Signaling Tech-
nology (Danvers, MA, USA) PD-L1 E1L3N, catalog
#13684 (5.4 μg/mL) and Abcam (Cambridge, MA, USA)
PD-L1 SP142, catalog #228462 (0.44 μg/mL) as laboratory
developed tests using EnVisionTM FLEX detection (High
pH) on the Autostainer Link 48 (Agilent). Immunostaining
for pan-cytokeratin (pan-CK) was assessed as a control
using an antihuman Cytokeratin, clone AE1/AE3, ready to
use (Agilent; Catalog #IR053). A representative section
from each block was stained for hematoxylin and eosin
(H&E) on day 0 of each experiment. All stained tissue
sections were scanned on an Aperio ScanScope AT Slide
Imager (Leica Biosystems; Buffalo Grove, IL, USA) at ×40
magniﬁcation, and images viewed on Aperio ImageScope
(v12.3.2) [28].
Assessment of immunostaining
Expression of PD-L1 was assessed by pathologists trained
and experienced in its interpretation according to inter-
pretation guides where appropriate for NSCLC and gastric
specimens [10–12, 29, 30]. For the 22C3, 28-8, and E1L3N
anti-PD-L1 clones, a tumor proportion score (TPS) was
calculated from the number of PD-L1 positive TCs as a
proportion of all TCs and expressed as a percentage.
Interpretation of the SP142 anti-PD-L1 antibody clone
involved both TC and immune cell (IC) scoring, and was
expressed as both a TPS and TC/IC score according to the
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established interpretation guidelines [12]. Gastric carcinoma
specimens were assigned a combined positive score (CPS)
that counts positive tumor and relevant ICs [30]. All spe-
cimens had PD-L1 and CK immunostaining assessed using
the Aperio ImageScope integrated image analysis ‘Positive
Pixel Count v9’ [31] algorithm to give an objective mea-
surement of expression. The number of positive pixels taken
as a proportion of the total number of tissue pixels was used
to deﬁne the positivity score and given as either absolute
values (positivity index) or as a percentage change relative
to the corresponding sample at day 0 (positivity %).
Accelerated degradation of unstained sections
Unstained sections of tissue were placed in a custom-built
acceleration chamber contained within an incubator
(Panasonic MIR-154-PA, Seacaucus, NJ, USA) without
direct light exposure where humidity, oxygen concentra-
tion, and temperature could be regulated and measured.
Environmental conditions of 37 °C, 100% oxygen, and
humidity of ~80% (range 75–85%) were used as baseline
parameters to achieve accelerated loss of detectable
antigen as measured by IHC. Oxygen concentration
was maintained and monitored using an oxygen meter
[Apogee Instruments Oxygen Meter (MO-200); Logan,
UT, USA] and humidity levels were measured using a
Lockdown Hygrometer (Lockdown Vault Accessories;
Columbia, MO, USA). Sections stored within the
incubator were removed at appropriate time points for
IHC staining alongside control sections stored in normal
archival conditions (RT, atmospheric oxygen, and
humidity). Repeat experiments of environmental effect on
antigen degradation involved the change of these para-
meters individually. Experiments exploring the use of
desiccant to protect against chamber conditions involved
comparing antigen expression in sections placed within
the chamber in a closed box, sealed in a protective bag
(Minigrip Commercial LLC UV Protection Bag; Alphar-
etta, GA, USA) with desiccant (Fisherbrand Humidity
Sponge Desiccant; Lenexa, KS, USA) and a humidity
indicator card (WiseSorbent Technology (Marlton, NJ,
USA)), to sections placed within the chamber without
additional protection, as well as to sections stored under
normal archival conditions.
Peptide standards for MS
Synthetic, isotopically labeled PD-L1 peptide standards
LQDAGVYR and AEVIWTSSDHQVLSGK containing
U-13C6, U-
15N4-arginine, or U-
13C6, U-
15N2-lysine at the
C-termini and unlabeled peptide standards were purchased
from New England Peptide (Gardner, MA, USA). Isotope
labeled peptides were of greater than 99% and 95% isotopic
and chemical purity, respectively; absolute concentration
was determined by amino acid analysis.
MS analyses
PD-L1 was analyzed by targeted MS as described pre-
viously [27] with the following modiﬁcations. To establish
elution of oxidized tryptophan forms of the AEVIWT
SSDHQVLSGK peptide, an aliquot of the peptide standard
was treated with 1.5% hydrogen peroxide at RT for 1 min
and then evaporated to dryness under vacuum. This stan-
dard contained a mixture of unoxidized AEVIWTSSDH
QVLSGK and the tryptophan oxidation products AEVI[W+
4]TSSDHQVLSGK (kynurenine form) and AEVI[W+ 16]
TSSDHQVLSGK (monooxygenated form). Each sample
analysis began with 100 µg tissue protein and after digestion
was spiked with 50 fmol each of the labeled LQDAGVYR
standard and the AEVIWTSSDHQVLSGK and oxidation
product mixture. Tryptic peptide digests were fractionated by
basic reverse phase liquid chromatography with disposable
spin columns (Pierce™ High pH Reversed-Phase Peptide
Fractionation Kit, Thermo Scientiﬁc, Rockford, IL, USA)
according to the manufacturer’s instructions.
Targeted MS analyses were performed on an Orbitrap
Fusion Lumos Tribrid™ instrument (Thermo Scientiﬁc,
Bremen, Germany) equipped with an Easy nLC™ 1200
liquid chromatograph and a Nanospray Flex™ ion source
(Thermo Scientiﬁc, San Jose, CA). Reverse phase liquid
chromatography was done with a PepMap RSLC C18-3
micron column, 75 μm × 15 cm, eluted at 250 nL/min with
a mobile phase gradient consisting of solvent A (0.1%
aqueous formic acid) and solvent B [0.1% formic acid in
water/acetonitrile (1:4, v/v)]. The mobile phase was
initially 5% B and then programmed to 20% B over
18 min, to 35% B over 14 min and ﬁnally to 95% B over
5 min before recycling to starting composition. Targeted
MS analysis was done by parallel reaction monitoring on
the Lumos. The acquisition method consisted of a full
scan selected ion monitoring event followed by targeted
MS2 scans as triggered by a scheduled inclusion list, with
a 5 min retention time window containing the precursor
m/z values. Retention times were determined from prior
analyses of synthetic peptide standards. The MS1 scan
was collected at a resolution of 30,000, an automatic gain
control (AGC) target value of 5e4, and a scan range from
m/z 350 to 1000. MS1 data were recorded in proﬁle mode.
The MS1 scan was followed by targeted MS2 collision
induced dissociation scans at a resolution of 30,000, an
AGC target value of 5e4, 1.6 m/z isolation window,
activation Q of 0.25 and an optimized collision energy for
each target of 30%. MS2 data were recorded in proﬁle
mode. Parallel reaction monitoring transitions were
extracted from raw dataﬁles and analyzed with Skyline
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[32]. Peptide peak areas were calculated as the sum of
three most abundant transitions. Peptide abundance was
calculated from the ratio of peak area for the unlabeled
endogenous peptide to the labeled internal standard.
Global proteome analyses were performed on unfractio-
nated tryptic digests of the same samples with the same MS
instrument, chromatography system and source. Reverse
phase liquid chromatography was performed with a Pep-
Map RSLC C18-3 micron column, 75 μm × 30 cm, eluted at
250 nL/min with a mobile phase gradient consisting of
solvent A (0.1% aqueous formic acid) and solvent B [0.1%
formic acid in water/acetonitrile (1:4, v/v)]. The mobile
phase was initially 6% B and then programmed to 27% B
over 27 min, to 40% B over 40 min, and ﬁnally to 95% B
over 8 min before recycling to starting composition. An
MS1 scan was collected at a resolution of 120,000, an AGC
target value of 4e5, a maximum injection time of 50 ms, and
a scan range from m/z 375 to 1500. MS1 data were recorded
in proﬁle mode. MS2 high-energy collision induced dis-
sociation scans were acquired at an AGC target value of
1e4, a maximum injection time of 35 ms, and with an iso-
lation window of 1.2m/z. Tandem MS scans were acquired
as centroided data. Peptide sequence identiﬁcation from
tandem mass spectra was done as described previously [33],
except that the search engine for peptide-spectrum matches
was MS-GF+ [34]. Peptide-spectrum matches were per-
formed with an FDR threshold of 1%, and required at least
two distinct peptide identiﬁcations per protein identiﬁcation.
Protein abundance differences were calculated from spectral
counts.
Statistical analysis
Statistical analysis was performed using IBM SPSS sta-
tistics software, version 25 (IBM Corp, Armonk, NY,
USA). Comparisons of multiple groups over time were
performed using repeated measures ANOVA with Bon-
ferroni correction and Tukey’s post-hoc analysis. Com-
parisons of two groups at a single point were performed
using independent samples or paired Student’s t test as
appropriate. Relationships between variables were asses-
sed using Pearson’s correlation and, if appropriate, linear
regression. Analysis of the effect of incubation conditions
on methionine oxidized peptides compared the baseline
condition and day 28 accelerated degradation condition
and used peptide count data for peptides with at least ten
spectral counts using Fisher’s exact test (two-sided).
The Wilcoxon Signed Rank test was used to determine
signiﬁcance in the number of oxidized peptides between
the baseline and day 28 conditions. Analyses of spectral
counts were performed using R software for statistical
computing (version 3.4.3) and all signiﬁcances were taken
as p < 0.05.
Results
Natural timeline of PD-L1 loss under normal storage
conditions
To conﬁrm the PD-L1 immunoreactivity loss in stored tis-
sue sections that has been reported in literature could be
reproduced in our laboratory, TMA sections containing 35
gastric carcinomas stored in archive over 24 months under
normal ambient conditions were stained for PD-L1 using
E1L3N and SP142 clones. Positive pixel count scoring
(positivity) demonstrated that E1L3N detected PD-L1 with
a greater sensitivity than SP142 (average positivity score
0.197 vs 0.128; p < 0.001), but both clones showed sig-
niﬁcant loss of PD-L1 expression over time as expected
(average positivity score E1L3N at 4.5 months and
24 months 0.197 vs 0.107; p= 0.05, 0.197 vs 0.070; p <
0.001; SP142 at 4.5 months and 24 months 0.128 vs 0.075;
p < 0.001, 0.128 vs 0.074; p < 0.001). Examples are
shown in Fig. 1a–c. CPS assessments for the gastric cancer
TMAs were higher on average for E1L3N than for SP142
(CPS 40 vs 30; p < 0.05). Clinically relevant loss of
CPS (from ≥1% to <1%) was seen by 4.5 months for both
clones (E1L3N 13% of cases, SP142 20% of cases) with
further loss by 24 months (E1L3N 33% of cases, SP142
37% of cases).
PD-L1 loss under accelerated conditions
To determine whether the natural loss of immunoreactivity
could be reproduced in an accelerated fashion, tissues were
subjected to controlled environmental stress. Storing
unstained sections of the NSCLCs in the acceleration
chamber at 100% oxygen, 37 °C, and 80% humidity
resulted in repeatable stepwise loss of PD-L1 expression
over 28 days comparable with loss, in effect, seen over
24 months in ambient conditions (Fig. 1d–f).
The NSCLC tissues were stained and assessed for PD-L1
expression using multiple antibody clones. Image analysis
of these demonstrated day 0 PD-L1 expression was broadly
equivalent for 22C3 and 28-8, with a slightly increased
average expression for E1L3N, and markedly lower average
expression for SP142. For the 22C3, 28-8, and E1L3N
clones a stepwise loss of PD-L1 expression is seen over
28 days within the acceleration chamber. The low immu-
nostaining by SP142 at day 0 resulted in minimal further
detection of expression decrease across NSCLC specimens
thereafter. (Supplementary Fig. S1).
PD-L1 expression by TPS found similar numbers of
positive (TPS ≥ 1%) and strongly positive (TPS ≥ 50%)
cases when assessed with the 22C3 (seven and four cases,
respectively), 28-8 (nine and four cases, respectively), and
E1L3N (9 and 5 cases, respectively) clones, but fewer
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positive and strongly positive cases for SP142 (three and
one, respectively). Loss of PD-L1 TPS in NSCLC sections
to levels below these prescribing guideline cutoffs occurred
for all clones at varying time points, with over half of cases
changing from diagnostically positive to diagnostically
negative by day 19 for 22C3 (TPS ≥ 1% and ≥50%), day 9
for 28-8 (TPS ≥ 1% and ≥50%), and day 9 for positive and
day 19 for strongly positive for E1L3N (Fig. 2).
Effect of environmental conditions on
immunoreactivity loss by IHC assessment
In order to further understand the relative contribution of
major environmental conditions on tissue immunoreactivity,
the effect of oxygen, humidity, and temperature on PD-L1
(E1L3N) and pan-CK (AE1/AE3) IHC expression was
assessed on tonsil and placenta tissue sections stored in the
acceleration chamber set to baseline conditions of 100%
oxygen, 37 °C, and 80% humidity over 28 days. By day
28 signiﬁcant loss of PD-L1 and pan-CK positivity was
seen in both tissues (average positivity day 0 vs day 28: PD-
L1 in placenta 0.528 vs 0.088 (100% vs 17%); p < 0.001,
tonsil 0.123 vs 0.018 (100% vs 15%) p < 0.001; CK in
placenta, 0.626 vs 0.259 (100% vs 41%); p= 0.05, tonsil
0.319 vs 0.219 (100% vs 69%); p < 0.05). Control slides
kept at normal ambient conditions had no signiﬁcant loss of
either PD-L1 or pan-CK expression by day 28 for both
placenta and tonsil tissue.
Changing the temperature in the acceleration chamber
had a signiﬁcant impact on the rate of IHC signal loss.
Increasing the temperature to 60 °C (in the context of ele-
vated oxygen and humidity) resulted in extremely rapid loss
of PD-L1 expression: (day 7 PD-L1 expression reduced to
8% and 3% positivity in placenta and tonsil respectively;
graph not shown). Conversely, decreasing the temperature
to 20 °C reduced immunoreactivity loss, resulting in no
statistically signiﬁcant loss of PD-L1 in placenta tissue by
day 28 (average positivity, 0.538 vs 0.257 (100% vs 48%);
p= 0.174) or pan-CK in both placenta and tonsil tissue
(average positivity, placenta 0.615 vs 0.215 (100% vs
35%); p= 0.284, tonsil 0.293 vs 0.247 (100% vs 84%);
p= 0.423) with a signiﬁcant reduction seen only for PD-L1
expression in tonsil by day 28 (average positivity 0.135 vs
0.07 (100% vs 52%); p < 0.05) though this was signiﬁcantly
less than the loss seen under 37 °C conditions (average
positivity of PD-L1 in tonsil by day 28, 20 °C vs 37 °C:
0.07 vs 0.02 (52% vs 14%); p < 0.05), results summarized
in Fig. 3a–d.
Reducing humidity had a signiﬁcant impact on the rate of
IHC signal loss. Decreasing humidity to 45% (in the context
of elevated oxygen and temperature) resulted in no sig-
niﬁcant loss of PD-L1 expression in placenta at 39 weeks
Fig. 1 PD-L1 expression in aged tissue and tissue under acceler-
ated conditions. Representative PD-L1 expression assessed by
E1L3N IHC in FFPE gastric carcinoma under normal atmospheric
conditions (a–c) and in NSCLC under acceleration conditions (d–f).
a Day 0, b 4.5 months, c 24 months; d Day 0, e Day 9, f Day 28.
PD-L1 programmed-death-ligand-1, IHC immunohistochemistry,
FFPE formalin-ﬁxed, parafﬁn embedded, NSCLC non-small cell lung
cancer.
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(0.639 vs 0.408 (100% vs 64%); p= 0.201) and required
28 weeks for a signiﬁcant loss in tonsil to occur (0.183 vs
0.021 (100% vs 10%); p < 0.05). The rate of PD-L1
expression loss in reduced humidity conditions was slo-
wed to the extent that both placenta and tonsil tissue
demonstrated loss by 39 weeks at 45% humidity similar to,
or less than, 1 week at 80% humidity (average positivity for
placenta 0.41 vs 0.17 (64% vs 27%); p= 0.13, and tonsil
0.018 vs 0.019 (10% vs 10%); p= 0.93). Average positivity
of PD-L1 in placenta and tonsil at 28 days under 45% and
80% humidity are shown in Fig. 3e–f.
Reducing oxygen levels in the incubation chamber to
20% (in the context of elevated temperature and humidity)
had no signiﬁcant effect on the rate or total quantity of
either PD-L1 or pan-CK expression in either placenta or
tonsil tissue (day 28 positivity, 100% vs 20% oxygen:
PD-L1, placenta 0.074 vs 0.08 (14% vs 16%); p= 0.918;
tonsil 0.0079 vs 0.016 (7% vs 14%); p= 0.937; pan-CK,
placenta 0.43 vs 0.45 (68% vs 71%) p= 0.918; tonsil
0.21 vs 0.22 (61% vs 64%); p= 0.937). Results shown in
Supplementary Fig. S2.
Effect of desiccant on preventing immunoreactivity
loss
Because humidity was determined to be a major factor in
loss of tissue immunoreactivity, the effect of storing slides
with or without desiccant in the acceleration chamber set
to baseline conditions of 100% oxygen, 37 °C and 80%
humidity over 28 days was examined. This was accom-
plished by measuring the expression of PD-L1 (E1L3N)
and pan-CK IHC using positive pixel count scoring
(positivity) on placenta and tonsil tissue sections stored
over 28 days.
Upon removal of slides from the sealed container stored
within the acceleration chamber, the humidity level was
recorded as <30% using the enclosed indicator card. Slides
stored with desiccant showed no signiﬁcant loss of either
PD-L1 or pan-CK expression in any tissue at day 28
(Average positivity day 0 vs day 28: PD-L1 in placenta 0.57
vs 0.53 (100% vs 93%); p= 0.083, tonsil 0.088 vs 0.073
(100% vs 83%); p= 0.555, pan-CK in placenta, 0.74 vs
0.72 (100% vs 97%); p= 0.311, tonsil 0.33 vs 0.30 (100%
vs 91%); p= 0.185).
Qualitative assessment of sections showed slides stored
with desiccant demonstrate expression loss similar to sec-
tions stored under normal atmospheric conditions, with
appreciable loss of PD-L1 expression in sections stored
without desiccant (Figs. 4 and 5). To a lesser extent, loss of
pan-CK was observed (Supplementary Fig. S3a, b). Sig-
niﬁcant loss of PD-L1 immunoreactivity was seen for pla-
centa tissue stored within the acceleration chamber, with
appreciable, but nonstatistically signiﬁcant loss demon-
strated in tonsil tissue. (Supplementary Fig. S4)
PD-L1 immunoreactivity loss on speciﬁc cell types
Tonsil tissue stained for PD-L1 with E1L3N stored in the
acceleration chamber with conditions of 100% oxygen, 80%
humidity and 37 °C over 28 days was assessed for expres-
sion loss difference between crypt epithelium cells and ICs
associated with germinal centers. Day 0 sections showed
strong staining within the crypt epithelium, and weaker
staining within the geminal centers, in keeping with known
Fig. 2 PD-L1 by clinical
cutoffs in FFPE NSCLC
sections over time in the
acceleration chamber with
conditions of 100% oxygen,
80% humidity, and 37 °C for
22C3, 28-8, E1L3N, and SP142
PD-L1 clones. Bars represent
number of cases in series with
PD-L1 expression equal or
above TPS clinical cutoff
thresholds. PD-L1 programmed-
death-ligand-1, TPS tumor
proportion score, TC tumor cell,
NSCLC non-small cell lung
cancer, FFPE formalin-ﬁxed,
parafﬁn embedded.
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Fig. 3 PD-L1 expression in
NSCLC under varying
accelerated conditions.
Placenta and tonsil FFPE
sections incubated in the
acceleration chamber under
different environmental
conditions at day 28; a–d: 100%
oxygen and 80% humidity at
either 20 °C or 37 °C, then
stained for PD-L1 (E1L3N) or
pan-CK (AE1/AE3): a Placenta
PD-L1, b Tonsil PD-L1,
c Placenta pan-CK, d Tonsil
pan-CK. 100% oxygen and
37 °C at either 45% or 80%
humidity at day 28, e Placenta
PD-L1, f Tonsil PD-L1. Control
conditions: 20 °C, atmospheric
humidity and oxygen. Bar
represents mean ± SEM. *p <
0.05, **p < 0.01, ***p < 0.001.
PD-L1 programmed-death-
ligand-1, CK cytokeratin, FFPE
formalin-ﬁxed, parafﬁn
embedded.
Fig. 4 PD-L1 expression by E1L3N in FFPE placenta sections at
days 0, 1, 3, 7, 14, 21, and 28. The ﬁrst row shows tissue sections
stored under normal atmospheric conditions, the second and third row
show tissue sections within an incubator at 100% oxygen, 37 °C, and
80% humidity without (second row) and with (third row) desiccant.
PD-L1 programmed-death-ligand-1, FFPE formalin-ﬁxed, parafﬁn
embedded.
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PD-L1 expression variation between these cell types [29].
Loss is seen in a stepwise fashion over time, with no dif-
ference in the rate of loss seen between the crypt epithelia
and the germinal centers (Supplementary Fig. S5). Due to
the weaker immunoreactivity associated with these ICs at
baseline; however, signal loss in this cell type was appre-
ciated earlier in the time course and was particularly
noticeable when scanning tissues at lower magniﬁcation.
This observation suggests clinical scoring guidelines that
rely upon characterization of weaker staining cells may be
impacted differentially by storage conditions.
Targeted MS analyses of PD-L1
To test the hypothesis that peptide oxidation is a major
contributor to loss of PD-L1 immunoreactivity in stored
tissues, targeted MS analyses of PD-L1 peptides were per-
formed to measure PD-L1 protein abundance in specimens
stored in normal atmospheric conditions or within the
acceleration chamber with conditions of 100% oxygen,
37 °C, and 80% humidity. Two PD-L1 peptides were ana-
lyzed, LQDAGVYR and AEVIWTSSDHQVLSGK, both
of which are in the extracellular domain of PD-L1. Whereas
LQDAGVYR contains no easily oxidizable residues,
AEVIWTSSDHQVLSGK contains an oxidizable trypto-
phan (W) and lies within the recognition sequence for the
22C3 antibody [35]. It has been shown previously that
measurement of the LQDAGVYR peptide in FFPE mela-
noma specimens yielded PD-L1 abundance comparisons
similar to those obtained by IHC with the E1L3N antibody
[27]. Thus, for these MS analyses, the LQDAGVYR
peptide was measured to quantify the abundance of PD-L1
protein, whereas the AEVIWTSSDHQVLSGK was mea-
sured as an oxidation-sensitive site. Moreover, we mon-
itored W oxidation products of AEVIWTSSDHQVLSGK
to detect oxidative changes that could affect the 22C3
recognition site. Representative MS traces for the peptides
and the oxidation product are shown in Supplementary
Fig. S6.
MS measurements of PD-L1 peptide LQDAGVYR at
baseline yielded protein abundance estimates concordant
with IHC with the 22C3 antibody (r2= 0.744, p= 0.001)
(Fig. 6). MS analyses of LQDAGVYR and
AEVIWTSSDHQVLSGK at baseline and at 9 and 28 days
of the acceleration protocol indicated that PD-L1 levels
were not decreased in the NSCLC samples, in contrast to
IHC measurements (Fig. 7). We noted that variation in
measured PD-L1 abundance appeared to be increased in the
9 and 28 day samples. This effect may reﬂect inconsistent
recovery of the labeled standard peptides in the samples
subjected to the acceleration protocol. Nevertheless, com-
parison of the MS peak areas for the endogenous PD-L1
peptide at baseline, 9 and 28 days did not reveal
any apparent loss of PD-L1 protein with incubation time
(Supplementary Fig. S7).
Oxidation of PD-L1 tryptophan residue in
AEVIWTSSDHQVLSGK would occur within the 22C3
recognition sequence and might affect antibody binding.
Hydrogen peroxide treatment of the AEVIWTSSDHQV
LSGK labeled standard yielded the kynurenine form
AEVIW[+4]TSSDHQVLSGK as the predominant product.
In MS analyses of the 28 day incubated samples, we
Fig. 5 PD-L1 expression by E1L3N in FFPE tonsil sections at days
0, 1, 3, 7, 14, 21, and 28. The ﬁrst row shows tissue sections stored
under normal ambient conditions, the second and third row shows
tissue sections within an incubator at 100% oxygen, 37 °C and 80%
humidity without (second row) and with (third row) desiccant. PD-L1
programmed-death-ligand-1, FFPE formalin-ﬁxed, parafﬁn embedded.
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detected the AEVIW[+4]TSSDHQVLSGK labeled stan-
dard, but not any oxidized peptide from the NSCLC sam-
ples (Supplementary Fig. S6).
To further test the hypothesis that the acceleration
chamber produced oxidation of proteins in FFPE sections
that interferes with immunoreactivity by IHC, we performed
global MS analyses of four samples each of the baseline and
day 28 samples from the acceleration chamber experiment,
as well as two samples each from placenta and tonsil stored
as unstained sections under ambient conditions for 2 years.
We extracted data for a set of 274 methionine-containing
peptides that were found in all samples in both reduced and
oxidized forms and compared abundances as the log2 ratio
of spectral counts for both forms (Fig. 8). Shifts in dis-
tributions to values greater than 1 indicated increased oxi-
dation. Though the distributions overlapped substantially,
the effect of 28 day wet oxidation was signiﬁcant (Dunn’s
test, adj. p= 9 × 10−14). The distributions for ambient
stored placenta and tonsil were similar to the 28 day wet
oxidized NSCLC from the acceleration chamber [Dunn’s
test (adj. p= 1 × 10−34 (tonsil vs wet oxidation baseline));
adj p= 8 × 10−58 (placenta vs. wet oxidation baseline)].
Although these global data indicate the presence of statis-
tically signiﬁcant oxidation, the distributions clearly indi-
cate a modest overall degree of oxidation that could not
account for the near-complete loss of PD-L1 IHC staining
observed.
Discussion
The loss of immunostaining in archived FFPE tissue is a
well-known but poorly understood phenomenon [22]. The
role of IHC in the analysis of predictive biomarkers has
increased the precision required for the use of immunos-
taining techniques, and the challenges of these are well
illustrated in the difﬁculties of using PD-L1 IHC as a pre-
dictive biomarker of response to anti-PD-1/PD-L1 immune
Fig. 7 MS quantitation of PD-L1 peptides LQDAGVYR (LQD)
and AEVIWTSSDHQVLSGK (AEV) in FFPE sections incubated
in accelerated loss chamber at baseline (0), 9 and 28 days of
incubation.MS mass spectrometry, PD-L1 programmed-death-ligand-
1, FFPE formalin-ﬁxed, parafﬁn embedded.
Fig. 6 Correlation of PD-L1 protein expression by immunohis-
tochemistry (by TPS) with PD-L1 abundance measured by MS in
FFPE sections prior to incubation in the accelerated loss chamber.
PD-L1 programmed-death-ligand-1, TPS tumor proportion score, MS
mass spectrometry, FFPE formalin-ﬁxed, parafﬁn embedded.
Fig. 8 Global proteome analyses to assess proteome-wide oxidation
under baseline (wet ox baseline) and acceleration conditions (wet
ox day 28) compared with samples of naturally aged placenta and
tonsil tissue stored under normal ambient conditions. The plotted
values are log2 ratios of numbers of MS/MS spectra corresponding to
oxidized and unoxidized methionine-containing peptides. Higher log2
ratios correspond to greater extent of proteome oxidation.
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checkpoint inhibitors [7]. The apparent loss of PD-L1
expression in aged specimens has raised justiﬁable concerns
about the use of older tissue blocks and sections. This
concern has led to guidance to use new tissue blocks where
possible and test sections as soon as they are prepared, with
varied recommendations between both speciﬁc PD-L1
clones and tissue types [10–13, 36].
The loss of antigen immunoreactivity has been observed
to vary between different antigens within and between tis-
sue types, with no obviously consistent factors that may
help predict the most sensitive antigens. Both polyclonal
and monoclonal antibodies may be affected, and loss occurs
in IHC assays that target the nucleus, cytoplasm, or mem-
branes of cells. Speciﬁc IHC signal loss can vary between
studies depending on factors such as ﬁxation and the spe-
ciﬁc antibodies used [3, 16, 18–21, 37–39].
Mechanisms of antigen degradation have been
explored previously, with a variety of potential factors
thought to inﬂuence the loss, including: preanalytical
variables, oxidation, humidity, and high temperature
[16, 20, 22–24, 40, 41]. We demonstrated with MS that there
is no detectable loss of the PD-L1 protein peptides measured
in stored tissues, even when IHC demonstrated major
reductions in quantity and intensity of immunoreactivity.
Therefore, conformational changes to the antigens them-
selves are more likely to account for the reduction seen.
The role of oxidation in antigen degradation has been
suggested previously [20, 40], and our global proteome
analyses indicate that conditions that facilitate accelerated
wet-air oxidation caused a statistically signiﬁcant degree of
oxidation that was similar to that seen in placenta and tonsil
samples stored under ambient conditions for 2 years.
However, this extent of oxidation was likely insufﬁcient to
account for the reduction in PD-L1 immunostaining by IHC
either in the acceleration experiments, or under normal
ambient storage conditions. Furthermore, we found no
evidence that changing the storage conditions from low-to-
high oxygen content affected PD-L1 or pan-CK detection
by IHC to any signiﬁcant degree.
Previous work suggested that humidity or the
ﬁxation process can have an effect on antigen degradation
[23, 42–44]. Formaldehyde ﬁxation results in multiple
crosslinking interactions that can involve proteins or DNA
and chromatin [44–46], but aldehyde induced crosslinks are
susceptible to spontaneous hydrolysis, a process catalyzed
by higher temperature [47, 48]. Our ﬁndings are consistent
with previous reports that the presence of water and high
temperature are a major cause of antigen loss in FFPE tissue
[16, 23, 49]. Therefore, one mechanism by which antigen
expression may be lost is heat catalyzed hydrolysis of
susceptible protein–protein crosslinks, resulting in a change
in crosslinked protein structures and loss of discontinuous
epitope sites or masking of linear sites.
The crosslinking process increases accessibility to some
antigens and renders others inaccessible through masking
of epitopes [42, 50]. The mechanism of crosslinking and
antigen masking is not fully characterized, but the masking
of antigens in FFPE tissue is more likely with speciﬁc
amino acid sequences [51, 52], and, importantly, dis-
continuous epitopes [52, 53] that are also particularly
susceptible to loss in high temperatures [43]. PD-L1
expression loss in archived tissue has been seen in pre-
vious studies [1, 8, 9, 54], and our results are aligned.
Anti-PD-L1 IHC clones detect a variety of epitope regions,
many of which are believed to be discontinuous (28-8,
SP263, and SP142) [37, 55, 56], possibly explaining why
PD-L1 IHC is particularly sensitive to loss of immunor-
eactivity. An alternative explanation for this observation
includes the possibility that the extracellular epitopes
recognized by 22C3 and 28-8 are particularly accessible,
and therefore are more susceptible to environmental
humidity during tissue storage.
Tissue processing and antigen retrieval prior to IHC
involves dehydration and a rehydration of tissue, which
has been demonstrated to be a crucial step in achieving
successful IHC assay outcomes [43, 57]. Interestingly, the
effect observed with the acceleration chamber was
prevented with the use of desiccant stored alongside
the sections, to the extent that the minimal loss of
immunoreactivity is similar to that in sections stored
under normal ambient conditions. This suggests that
humidity during storage is a major driving force behind
immunoreactivity loss. This may be due to epitope con-
formational changes driven by hydration, which occurs
over time during storage, but is not of the same nature as
the rehydration of tissue that occurs during antigen
retrieval immediately prior to immunohistochemical
staining. The practical implications of this ﬁnding are
signiﬁcant: desiccant may provide an effective method
of preventing antigen loss that could be immediately
implemented into clinical research protocols involving the
storage and transportation of tissue. This would provide
an attractive alternative to other more complicated, time-
consuming, and expensive methods of preventing loss
such as microwave heating, recoating in parafﬁn wax,
storage under vacuum, or the use of nitrogen chambers
[14, 20, 22, 24, 58].
This study has limitations. While over a thousand tissue
sections were included in the analysis, sample sizes were
small for some conditions, perhaps accounting for non-
statistically signiﬁcant trends in certain experiments. Posi-
tivity as deﬁned by pixel counting was complemented by
TPS/CPS scores in tumors to give clinical relevance, but the
equivalent is not possible in placenta and tonsil; therefore,
although signiﬁcant loss can be quantitatively demonstrated
with good reproducibility (Supplementary Figs. S8–S9,
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Supplementary Tables S1–S2), the point of clinically rele-
vant loss does not translate for these tissues. Although
PD-L1 expression by IHC did broadly correlate with MS
ﬁndings, not all cases did, and these discrepancies could be
accounted for by PD-L1 protein posttranslational mod-
iﬁcations including glycosylation [27] which may not be
detected by IHC but are detectable by MS. Labeled internal
peptide standards used in the targeted analysis of PD-L1
indicated that peak areas were reduced in some, but not all,
samples. While the cause of this is uncertain, we cannot rule
out the possibility that the accelerated degradation condi-
tions may have altered those specimens in a manner that
reduced recovery of the labeled standards. Inspection of the
MS peak areas for the endogenous PD-L1 peptides indi-
cated no loss of protein during accelerated incubation
(Supplementary Fig. S7). Finally, the acceleration incubator
has demonstrated that select environmental conditions
reproducibly affect the loss of IHC expression, but this has
focused on PD-L1 and pan-CK in speciﬁc tissues. The
application of this approach as a wider tool in understanding
antigen loss under ambient conditions, and the optimal
conditions to predict storage effect on novel biomarkers in
development requires further study.
To our knowledge, this is the ﬁrst study that has sys-
tematically used quantitative MS to characterize the impact
of tissue storage using a model system under controlled
conditions. We demonstrate that PD-L1 expression asses-
sed by IHC with different antibody clones undergoes signal
loss over time, and that this loss is largely accelerated by
humidity and high temperature, rather than by environ-
mental factors favoring oxidation. The use of an accelera-
tion process to mimic the natural loss of antigenicity that
occurs in naturally stored FFPE tissue sections may provide
a platform by which novel biomarker robustness can be
evaluated early in development. MS is a powerful techni-
que that overcomes the limitations of studying protein
expression in stored tissues sections by IHC alone. More-
over, MS may be ideally suited to analyze archival FFPE
specimens and conduct hypothesis testing in regards to the
abundance of protein drug targets with associated ther-
apeutic outcomes.
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